CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
AG-013736 +2 moredrug
Likely dose
AG-013736 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00735904
NCT00735904Phase 2Completed
CompareCT.gov

Phase 2 Trial Of AG-013736 As First-Line Treatment For Patients With Squamous Non-Small Cell Lung Cancer Receiving Treatment With Cisplatin And Gemcitabine

Pfizer·interventional·Posted Aug 15, 2008·Updated Jan 3, 2013

In Brief

A Phase 2 clinical trial evaluating AG-013736, gemcitabine, and 1 other intervention for Carcinoma, Non-Small-Cell Lung (NSCLC). Completed, enrolled 38 participants across 10 sites in 4 countries.

Detailed Summary

This study will evaluate whether AG-013736 when combined with cisplatin and gemcitabine shows activity and is safe in patients with squamous type of non-small cell lung cancer

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung (NSCLC)
CountriesPoland, Romania, South Africa, Ukraine
Collaborators--

Timeline

Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 15, 2008
Enrollment StartDec 1, 2008
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 17.9 years ago

Interventions

AG-013736drug

AG-013736 5 mg tablets orally, twice daily, until disease progression

gemcitabinedrug

200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m\^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles

cisplatindrug

1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m\^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles